Prescription medication · Anticonvulsant
cenobamate
Also sold as Xcopri. Xcopri is used to treat partial-onset seizures in adults.
Data updated 2026-05-15
- 6,460
- FDA reportsLightly reported
- 5
- InteractionsFew interactions
- $37.71
- Brand price (NADAC)
What the data shows
cenobamate (Xcopri) is a prescription Anticonvulsant, reported less often than most tracked drugs (6,460 FDA reports), with 5 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
cenobamate (Xcopri) is a prescription Anticonvulsant. Xcopri is used to treat partial-onset seizures in adults.
Xcopri is a medicine used to treat partial-onset seizures in adults. It works by reducing the irregular electrical activity in the brain that causes seizures.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$37.71/unit
Generic Available
No
SK LIFE
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Xcopri is used to treat partial-onset seizures in adults.
Common side effects
Feeling sleepy, Dizziness, Feeling tired
Key warnings
This medicine can cause a serious allergic reaction called DRESS, which can affect multiple organs.
The sections below are summarized in plain English from cenobamate's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Xcopri helps to control seizures by affecting brain activity. It reduces the excitability of brain cells. This helps to prevent the spread of seizure activity.
Side Effects (from patient reports)
Based on 6,460 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for cenobamate, by number of reports
- Seizure
Seizure
1,815 reports
- Fatigue 672
Fatigue
672 reports
- Somnolence 660
Somnolence
660 reports
- Dizziness 537
Dizziness
537 reports
- Fall 368
Fall
368 reports
- Headache 317
Headache
317 reports
- Drug Interaction 311
Drug Interaction
311 reports
- Feeling Abnormal 245
Feeling Abnormal
245 reports
- Gait Disturbance 242
Gait Disturbance
242 reports
- Balance Disorder 219
Balance Disorder
219 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for cenobamate each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where cenobamate sits
cenobamate has more FDA adverse-event reports than 29% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is cenobamate; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 6,460 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2019–2025.
Total Reports
6,460
Reports Mentioning Death
156
2.4% of reports — not proof of cause
Hospitalization Reports
1,300
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | SEIZURE | 1,815 |
| 3 | FATIGUE | 672 |
| 4 | SOMNOLENCE | 660 |
| 5 | DIZZINESS | 537 |
| 8 | FALL | 368 |
| 9 | HEADACHE | 317 |
| 10 | DRUG INTERACTION | 311 |
| 13 | FEELING ABNORMAL | 245 |
| 14 | GAIT DISTURBANCE | 242 |
| 15 | BALANCE DISORDER | 219 |
| 16 | NAUSEA | 201 |
| 17 | MEMORY IMPAIRMENT | 198 |
| 18 | RASH | 176 |
| 19 | HOSPITALISATION | 159 |
| 20 | VOMITING | 157 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This medicine can cause a serious allergic reaction called DRESS, which can affect multiple organs. It can also cause liver problems. Tell your doctor right away if you have a fever, rash, swollen lymph nodes, or yellowing of your skin or eyes. Xcopri may cause you to have suicidal thoughts or behaviors. Watch for changes in your mood.
Known Drug Interactions
( 7.1 ) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. phenobarbital ↑ plasma concentrations Because of a potential for an increase in the risk of adverse reactions from these drugs, consider a reduction in dosage of phenobarbital or clobazam, as clinically appropriate, when used concomitantly with XCOPRI.
Mechanism: Cenobamate causes the levels of phenobarbital in your blood to go up. This makes it more likely that you will have a bad reaction to the phenobarbital.
( 7.1 ) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. phenobarbital ↑ plasma concentrations Because of a potential for an increase in the risk of adverse reactions from these drugs, consider a reduction in dosage of phenobarbital or clobazam, as clinically appropriate, when used concomitantly with XCOPRI. desmethylclobazam, the active metabolite of clobazam ↑ plasma concentrations CYP2B6 Substrates ↓ plasma concentrations Because of a potential for reduced efficacy of these drugs, increase the dosage of CYP2B6 or CYP3A4 substrates, as needed, when...
Mechanism: Cenobamate increases the level of the active part of clobazam in your bloodstream. This can lead to more side effects from the clobazam.
( 7.1 ) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine ↓ plasma concentrations Because of a potential for reduced efficacy of these drugs, increase the dosage of lamotrigine or carbamazepine, as needed, when used concomitantly with XCOPRI.
Mechanism: Cenobamate speeds up how quickly your body breaks down lamotrigine, which lowers the amount of medicine in your blood. This can make the lamotrigine less effective at preventing seizures.
( 7.1 ) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine ↓ plasma concentrations Because of a potential for reduced efficacy of these drugs, increase the dosage of lamotrigine or carbamazepine, as needed, when used concomitantly with XCOPRI. carbamazepine ↓ plasma concentrations phenytoin ↑ plasma concentrations Because of a potential 2-fold increase in phenytoin levels, gradually decrease...
Mechanism: Cenobamate causes your body to process carbamazepine more quickly, leading to lower levels of the drug in your system. This could mean the medicine will not work as well to control your condition.
7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. carbamazepine ↓ plasma concentrations phenytoin ↑ plasma concentrations Because of a potential 2-fold increase in phenytoin levels, gradually decrease phenytoin dosage by up to 50% as XCOPRI is being titrated.
Mechanism: Cenobamate slows down the body's ability to clear phenytoin, which can cause the drug to build up to dangerous levels. This can lead to a two-fold increase in the amount of phenytoin in your blood.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I crush Xcopri tablets?
What should I do if I experience side effects?
Can I drink alcohol while taking Xcopri?
Will Xcopri interact with my birth control?
How often will my doctor check my liver function?
Can I drive while taking Xcopri?
What happens if I stop taking Xcopri suddenly?
How will my dose be adjusted?
What if I have kidney problems?
What if I have liver problems?
What are the common side effects of cenobamate?
Does cenobamate interact with other medications?
What drug class is cenobamate?
What pregnancy or breastfeeding source fields are listed for cenobamate?
Related Medications in Anticonvulsant
Other drugs grouped near cenobamate - same-class peers and common alternatives.
brivaracetam
Briviact
Brivaracetam is a medicine used to treat partial-onset seizures.
Compare with cenobamate →
cannabidiol
Epidiolex
Epidiolex is a medicine that contains cannabidiol.
Compare with cenobamate →
carbamazepine
Tegretol
Carbamazepine is a medicine used to control seizures and treat nerve pain.
Compare with cenobamate →
clobazam
Onfi, Sympazan
Clobazam oral suspension is a medicine used with other medicines to treat seizures caused by Lennox-Gastaut syndrome.
Compare with cenobamate →
clonazepam
Klonopin
Clonazepam is a medicine that belongs to the benzodiazepine class.
Compare with cenobamate →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for cenobamate: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 6,460.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 2.41%.
- sumatriptan Δ 0.07 pts · 36,885 reports · Triptan (Serotonin 5-HT1 Agonist) 2.35%death share
- liothyronine Δ 0.10 pts · 8,408 reports · Thyroid Hormone (T3) 2.32%death share
- canagliflozin Δ 0.12 pts · 29,554 reports · SGLT2 Inhibitor 2.29%death share
- progesterone Δ 0.15 pts · 21,004 reports · Progestogen Hormone 2.27%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on cenobamate
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for cenobamate
The FDA label for cenobamate (sold under brand names such as Xcopri) classifies it as a prescription-only medication in the Anticonvulsant class. Xcopri is used to treat partial-onset seizures in adults. Official labeling lists 5 commonly reported side effects, including Feeling sleepy, Dizziness, Feeling tired.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 6,460 voluntary reports. The database also lists 5 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: September 25, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages